MedTrace Logo

Anlotinib Neoadjuvant Treatment in Locally Advanced Thyroid Cancer

NCT04309136 · Status: UNKNOWN · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 13

Last updated 2021-04-01

No results posted yet for this study

Summary

To determine the efficacy and safety of Anlotinib in patients of locally advanced thyroid cancer in the neoadjuvant setting.

Conditions

Interventions

DRUG

Anlotinib

All patients will receive Anlotinib for at least two cycles of neoadjuvant treatment

PROCEDURE

surgery

Perform surgery if operable after neoadjuvant therapy

PROCEDURE

core needle biopsy

Perform core needle biopsy if inoperable after neoadjuvant therapy

Sponsors & Collaborators

  • Fudan University

    lead OTHER

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
14 Years
Max Age
80 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2019-06-01
Primary Completion
2021-02-01
Completion
2022-06-01

Countries

  • China

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04309136 on ClinicalTrials.gov